newsfilter
← Latest News
Business Wire·

RayzeBio, Inc. Announces Closing of Upsized $358 Million Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

RayzeBio, Inc. (NASDAQ:RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today announced the closing of its previously announced upsized $358 million